Meeting
2019 ASCO Annual Meeting
Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.
Authors
Jonathan W. Riess
UC Davis Comprehensive Cancer Center, Sacramento, CA
Jonathan W. Riess , Susan G. Groshen , Karen L. Reckamp , Heather A. Wakelee , Geoffrey R. Oxnard , Sukhmani Kaur Padda , Marianna Koczywas , Zofia Piotrowska , Lynette M. Sholl , Cloud P. Paweletz , Christie J. Lau , Jill Kolesar , Philip C. Mack , Jeffrey Moscow , Pasi A. Janne , Primo Lara Jr., Edward M. Newman , David R. Gandara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02496663
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9057)
DOI
10.1200/JCO.2019.37.15_suppl.9057
Abstract #
9057
Poster Bd #
380
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
First Author: Jonathan W. Riess
Poster
2023 ASCO Annual Meeting
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
First Author: Xiuning Le
Poster
2017 ASCO Annual Meeting
A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
First Author: Helena Alexandra Yu
Poster
2024 ASCO Annual Meeting
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: Shen Zhao